# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: k060503   
B. Purpose for Submission: New device   
C. Measurand: Calibrator for Tacrolimus assay   
D. Type of Test: Not applicable - Calibrator   
E. Applicant: DADE BEHRING, INC.   
F. Proprietary and Established Names: DIMENSION TACR CALIBRATOR   
G. Regulatory Information:

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>Regulation Section</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>DLJ</td><td rowspan=1 colspan=1>II</td><td rowspan=1 colspan=1>21 CFR 862.3200</td><td rowspan=1 colspan=1>Toxicology (91)</td></tr></table>

# H. Intended Use:

1. Intended use(s):

The Dimension $\textsuperscript { \textregistered }$ TACR Calibrator is an in vitro diagnostic product intended to be used to calibrate the Tacrolimus (TACR) method for the Dimension $\textsuperscript { \textregistered }$ clinical chemistry system.

2. Indication(s) for use:

The Dimension $\textsuperscript { \textregistered }$ TACR Calibrator is an in vitro diagnostic product intended to be used to calibrate the Tacrolimus (TACR) method for the Dimension $\textsuperscript { \textregistered }$ clinical chemistry system.

3. Special conditions for use statement(s): For prescription use

4. Special instrument requirements: Dade Dimension clinical chemistry system

# I. Device Description:

The Dimension TACR calibrator is a stabilized human whole blood hemolysate product containing tacrolimus. The kit consists of two vials of each calibrator level 1- 5. The target concentrations are approximately 0, 3, 6, 12, and $3 2 . 5 ~ \mathrm { n g / m L }$ tacrolimus.

The calibrators contain human blood components. Each lot was tested and found to be non-reactive for Hepatitis B Surface Antigen $\left( { \mathrm { H B s A g } } \right)$ , Antibodies to Human Immunodeficiency Virus 1 and 2 (HIV 1/2), and Antibody to Hepatitis C Virus (HCV).

# J. Substantial Equivalence Information:

<table><tr><td rowspan=1 colspan=2>Predicate</td><td rowspan=1 colspan=2>Abbott IMx Tacrolimus II CalibratorP970007</td></tr><tr><td rowspan=1 colspan=4>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=2>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=2>Calibrators intended foruse as a reference inmeasuring tacrolimuswith their respectiveassays.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=2>Whole blood hemolysate</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Device</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>Target concentrations</td><td rowspan=1 colspan=1>0, 3, 6, 12, and 32.5ng/mL</td><td rowspan=1 colspan=1>0, 3, 6, 12, 20, and 30ng/mL</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

<table><tr><td rowspan=1 colspan=4>GUIDANCE</td></tr><tr><td rowspan=1 colspan=1>Document Title</td><td rowspan=1 colspan=1>Office</td><td rowspan=1 colspan=1>Office Division</td><td rowspan=1 colspan=1>Web Page</td></tr><tr><td rowspan=2 colspan=1>Class II Special ControlsGuidance Document:Cyclosporine and TacrolimusAssays; Guidance for Industryand FDA</td><td rowspan=2 colspan=1>OIVD</td><td rowspan=2 colspan=1>DCTD</td><td rowspan=1 colspan=1>http://www.fda.gov/cdrh/ode/guidance/1380.html</td></tr><tr><td rowspan=1 colspan=1></td></tr></table>

# L. Test Principle:

Not applicable - calibrator

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility: Not applicable

b. Linearity/assay reportable range: Not applicable

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Purified tacrolimus powder and whole blood hemolysate and are used to prepare a stock solution. The master pool lots are prepared by diluting the stock to obtain specific target concentrations. The concentrations for the reference lot are assigned by LC/MS/MS. The target concentrations are approximately 0, 3, 6, 12, and $3 2 . 5 ~ \mathrm { { n g / m L } }$ tacrolimus.

Shelf-life and opened vial stability studies were conducted using real time data collected from three (3) lots of the TACR cartridge. The data from the sponsorâ€™s studies supported a shelf life of 12 months when the product is stored frozen (-15 to $- 2 5 ^ { \circ } \mathrm { C } )$ ) and opened vial stability of 30 days when the product is stored at $2 { - } 8 ^ { \circ } \mathrm { C }$ .

d. Detection limit: Not applicable   
e. Analytical specificity: Not applicable

f. Assay cut-off: Not applicable

2. Comparison studies:

a. Method comparison with predicate device: Not applicable

b. Matrix comparison: Not applicable

3. Clinical studies:

a. Clinical Sensitivity: Not applicable

b. Clinical specificity: Not applicable   
c. Other clinical supportive data (when a. and b. are not applicable): Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range: Not applicable

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information is this premarket notification is complete and supports a substantial equivalence determination.